596 |
BCL2, APOPTOSIS REGULATOR |
BCL2 |
Bcl-2 |
PPP1R50 |
151430 |
990 |
ENSG00000171791 |
OTTHUMG00000132791 |
P10415 |
BCL2_HUMAN |
APOPTOSIS REGULATOR BCL-2. [SOURCE:UNIPROT/SWISSPROT;ACC:P10415] |
Apoptosis regulator Bcl-2 |
PA25302 |
BCL2 apoptosis regulator |
T31309 |
59 |
Human Readable Name | DRUGGABLE GENOME |
Uniprot Evidence | 1: Evidence at protein level |
Interpro Type | Domain |
Interpro Name | Apoptosis regulator, Bcl-2, BH |
Uniprot Status | Swiss-Prot |
Interpro Short Name | Bcl2_BH |
Interpro Acc | IPR000712 |
Target Class | other |
Target Subclass | regulator of apoptosis |
Target Subclass | Other |
Transmembrane Helix Count | 1 |
Target Main Class | Other |
Gene Biotype | PROTEIN_CODING |
DRUG RESISTANCE |
DRUGGABLE GENOME |
CLINICALLY ACTIONABLE |
antisense oligonucleotide (inhibitory) |
Trial Name | Genasense |
Novel drug target | Established target |
Notes |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Apoptosis regulator Bcl-2 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Notes | |
Trial Name | obatoclax, GX15-070 |
Novel drug target | Established target |
n/a |
Trial Name | AT-101 |
Novel drug target | Established target |
n/a |
Trial Name | tesetaxel |
Novel drug target | Established target |
n/a |
Trial Name | ANG1005 |
Novel drug target | Established target |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Apoptosis regulator Bcl-2 inhibitor |
Notes |
n/a |
Trial Name | milataxel, MAC-321 |
Novel drug target | Established target |
n/a |
Trial Name | ortataxel |
Novel drug target | Established target |
inhibitor (inhibitory) |
Mechanism of Interaction | Apoptosis regulator Bcl-2 inhibitor |
Direct Interaction | yes |
n/a |
n/a |
n/a |
inhibitor (inhibitory) |
Notes |
BCL2 | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
BCL2 | Gene Symbol |
Target Class | other |
Target Subclass | regulator of apoptosis |
APOPTOSIS REGULATOR BCL-2. [SOURCE:UNIPROT/SWISSPROT;ACC:P10415] | Description |
ENSG00000171791 | Ensembl Gene Id |
BCL2 | Display Id |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
ENSG00000171791 | Ensembl Gene Id |
596 | Entrez Gene Id |
BCL2_HUMAN | Uniprot Id |
Uniprot Evidence | 1: Evidence at protein level |
Interpro Type | Domain |
Interpro Name | Apoptosis regulator, Bcl-2, BH |
DRUGGABLE GENOME |
596 | Entrez Gene Id |
ENSG00000171791 | Ensembl Gene Id |
P10415 | Uniprot Accession |
Target Subclass | Other |
Transmembrane Helix Count | 1 |
Target Main Class | Other |
PA25302 | PharmGKB ID |
596 | Entrez Gene ID |
59 | CIViC Gene ID |
DRUG RESISTANCE |
BCL2 | MyCancerGenome Gene Symbol |
BCL2 | MyCancerGenome Reported Gene Name |
BCL2 | GENE_SYMBOL |
Apoptosis regulator Bcl-2 | UNIPROT |
BCL-2 | Gene Symbol |
ENSG00000171791 | Gene Symbol |
BCL2 | Ensembl Id |
DRUGGABLE GENOME |
BCL2 | Gene Symbol |
CLINICALLY ACTIONABLE |
BCL-2 | TTD Gene Abbreviation |
T31309 | TTD Target ID |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |